EUVIMEDEUVIMED entdecken
Crossref

Orchestrating Tumor‐Immune Interface and Microenvironment Remodeling via a Tumor‐Preferential DNA Nano‐Regulator for Metabolic‐Immunotherapy

Chao‐Qiang Li, Wen‐Jia Shi, Yi‐Shan Liu, Hua‐Dong Li, Yan Zhang, Bin‐Cheng Yin, Pei‐Qiang Ma, Bang‐Ce Ye

Angewandte Chemie · 05.11.2026

DOI: 10.1002/ange.9465567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie, online erschienen am 05.11.2026. Verfasst von Chao‐Qiang Li und 7 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic reprogramming in malignant cells drives tumor progression and impairs immunotherapy efficacy, highlighting the urgent need for synergistic metabolic‐immunotherapy. However, the pharmacokinetic disparity and systemic toxicities pose significant challenges on this synergy. We develop a tumor‐preferential, multifunctional DNA nano‐regulator assembled on a DNA origami‐based framework with two functional layers for the integration of immune cues and metabolic modulation at the tumor‐immune interface. The inner layer is precisely functionalized with anti‐CD3/CD28/PD‐L1 antibodies and glutamine synthetase, enabling in situ T‐cell engagement, PD‐L1 blockade, and metabolic environment improvement. The outer layer combines albumin‐binding domains with pH‐responsive i‐motif switches to form a pH‐sensitive albumin coating in vivo, which shields the inner antibodies during systemic circulation and specifically exposes them within the tumoral acidic microenvironment. In the xenograft and syngeneic mouse models, the regulator‐mediated broad remodeling of the intratumoral immune and metabolic landscapes results in enhanced T‑cell infiltration and activation, potent tumor‐growth suppression, and a favorable safety profile. This study combines metabolic intervention with immunotherapy by integrating the synergism and tumor preference of therapies.

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Li, C., Shi, W., Liu, Y., Li, H., Zhang, Y., Yin, B., Ma, P., & Ye, B. (2026). Orchestrating Tumor‐Immune Interface and Microenvironment Remodeling via a Tumor‐Preferential DNA Nano‐Regulator for Metabolic‐Immunotherapy. Angewandte Chemie. https://doi.org/10.1002/ange.9465567

Vancouver

Li C, Shi W, Liu Y, Li H, Zhang Y, Yin B, et al. Orchestrating Tumor‐Immune Interface and Microenvironment Remodeling via a Tumor‐Preferential DNA Nano‐Regulator for Metabolic‐Immunotherapy. Angewandte Chemie. 2026. doi:10.1002/ange.9465567

BibTeX
@article{Li2026,
  author = {Li, Chao‐Qiang and Shi, Wen‐Jia and Liu, Yi‐Shan and Li, Hua‐Dong and Zhang, Yan and Yin, Bin‐Cheng and Ma, Pei‐Qiang and Ye, Bang‐Ce},
  title = {Orchestrating Tumor‐Immune Interface and Microenvironment Remodeling via a Tumor‐Preferential DNA Nano‐Regulator for Metabolic‐Immunotherapy},
  journal = {Angewandte Chemie},
  year = {2026},
  doi = {10.1002/ange.9465567}
}
Kostenlos starten →